Ivosidenib – Another Feather in the Hat of Treatment for Acute Myeloid Leukemia

Abstract

The treatment of acute myeloid leukemia has undergone a paradigm shift in the past few years. Multiple new targeted and nontargeted agents have been approved in the recent past. Isocitrate dehydrogenase (IDH) mutation is one such target that has been identified, and two new drugs, ivosidenib and enasidenib have been approved. The former is an IDH1 inhibitor, and the latter is an IDH2 inhibitor. The mechanism of action, key trials, adverse events, and monitoring of ivosidenib has been discussed in this article.

Keywords

Isocitrate dehydrogenase inhibitors - ivosidenib - new drugs in acute myeloid leukemia

Publication History

Received: 26 February 2020

Accepted: 03 May 2020

Article published online:
17 May 2021

• References

• 1 Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA. et al. Acute myeloid leukaemia: Challenges and real world data from India. Br J Haematol 2015; 170: 110-7
• 2 Kalaiyarasi JP, Ganesan P, Kannan K, Ganesan TS, Radhakrishnan V, Dhanushkodi M. et al. Outcomes of intensive treatment of adult acute myeloid leukemia patients: A retrospective study from a single centre. Indian J Hematol Blood Transfus 2019; 35: 248-54
• 3 Pant M, Bhatt VR. Early mortality and survival in older adults with acute myeloid leukemia. Int J Hematol Oncol 2017; 6: 61-3
• 4 Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P. IDH1-mutated relapsed or refractory AML: Current challenges and future prospects. Blood Lymphat Cancer Targets Ther 2019; 9: 19-32
• 5 Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ. et al. Acute myeloid leukemia with IDH1 or IDH2 mutations: Frequency and clinicopathologic features. Am J Clin Pathol 2011; 135: 35-45
• 6 DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T. et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 2015; 90: 732-6
• 7 Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation-Full Text View-ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT02074839 Available from: [Last accessed on 2020 Feb 26]
• 8 DiNardo CD, Stein EM, Botton Sde, Roboz GJ, Altman JK, Mims AS. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018; 378: 2386-98
• 9 Prior DJ. A study of the electrophysiological properties of the incurrent siphonal valve muscle of the surf clam, Spisula solidissima. Comp Biochem Physiol A Comp Physiol 1975; 52: 607-10
• 10 Study of AG-120 (Ivosidenib) vs. Placebo in Combination with Azacitidine in Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation-Full Text View-ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT03173248 Available from: [Last accessed on 2020 Feb 26]
• 11 IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-Mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation-Full Text View-ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT03564821 Available from: [Last accessed on 2020 Feb 26]
• 12 Birendra K, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk 2016; 16: 460-5
• 13 Highlights of Prescribing Information-Tibsovo® (Ivosidenib Tablets), for Oral Use; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf
• 14 Fan B, Mellinghoff IK, Wen PY, Lowery MA, Goyal L, Tap WD. et al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest New Drugs 2020; 38: 433-44